Skip to content

A exploratory controlled clinical study of Apatinib combined TACE in treating advanced hepatocellular carcinoma

A exploratory controlled clinical study of Apatinib combined TACE in treating advanced hepatocellular carcinoma

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPN-16009457
Enrollment
Unknown
Registered
2016-10-17
Start date
2016-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

Sponsors

the First affiliated Hospital of SooChow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years old; 2. Strictly comply with the "guidelines for primary liver cancer diagnosis and treatment" (2011 edition) clinical diagnosis standard or confirmed by histopathology or cytology examination in patients with unresectable HCC recurrence/metastasis, and can't accept palliative surgery or radiation therapy, and at least one measurable lesions; 3. The Child - Pugh, liver function grade: good grade A or B (7 points) or less; 4. The BCLC stage for B; 5. In group 1 weeks before ECOG PS score 0 and 1; 6. To be expected to survive a period of 12 weeks or more; 7. Major organs functioning; 8. Women of childbearing age should be in the group of 7 days before the pregnancy test; 9. Willing to join in this study, subjects signed informed consent, good adherence, cooperate with the follow-up.

Exclusion criteria

Exclusion criteria: 1. In the study of four weeks before received anything other than the conventional local treatment (including but not limited to surgery, radiotherapy, hepatic artery thrombosis, hepatic artery perfusion, radiofrequency ablation and cryoablation or percutaneous ethanol injection); 2. People with high blood pressure and antihypertensive drug therapy can not drop to normal range (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg); 3. The influence factors of oral drugs (such as unable to swallow, chronic diarrhea and intestinal obstruction, significantly affect the drug taking and absorb); 4. Pregnant or lactating women;Patients with fertility unwilling or unable to take effective contraceptive measures; 5. Have a mental illness, or psychiatric history of drug abuse. 6. Doctors considered to be not suitable for participating the study.

Design outcomes

Primary

MeasureTime frame
Progression-Free-Survival;

Countries

China

Contacts

Public ContactNi Caifang

the First affiliated Hospital of SooChow University

cjr.nicaifang@vip.163.com+86 13706200115

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026